questionsmedicales.fr
Tumeurs
Tumeurs primitives multiples
Tumeurs primitives multiples : Questions médicales fréquentes
Diagnostic
5
Néoplasmes
Diagnostic
Imagerie médicale
Imagerie par résonance magnétique
Tomodensitométrie
Biopsie
Marqueurs tumoraux
Néoplasmes
Biomarqueurs
Histologie
Néoplasmes
Caractéristiques cliniques
Antécédents familiaux
Néoplasmes
Facteurs de risque
Symptômes
5
Symptômes
Néoplasmes
Fatigue
Néoplasmes
Symptômes
Variabilité
Évolution
Néoplasmes
Surveillance
Diagnostic différentiel
Néoplasmes
Maladies
Localisation
Néoplasmes
Symptômes
Prévention
5
Prévention
Néoplasmes
Mode de vie
Dépistage
Néoplasmes
Prévention
Facteurs de risque
Néoplasmes
Prévention
Exposition
Substances chimiques
Néoplasmes
Dépistage génétique
Néoplasmes
Prédisposition
Traitements
5
Chirurgie
Chimiothérapie
Radiothérapie
Chimiothérapie
Néoplasmes
Stade
Immunothérapie
Néoplasmes
Système immunitaire
Radiothérapie
Néoplasmes
Traitement
Choix thérapeutique
Néoplasmes
État de santé
Complications
5
Complications
Néoplasmes
Effets secondaires
Récidive
Néoplasmes
Complications
Effets secondaires
Soins de soutien
Néoplasmes
Qualité de vie
Complications
Néoplasmes
Prévention
Complications
Surveillance
Facteurs de risque
5
Facteurs de risque
Néoplasmes
Carcinogènes
Mode de vie
Facteurs de risque
Néoplasmes
Infections
Facteurs de risque
Virus
Exposition professionnelle
Facteurs de risque
Néoplasmes
Facteurs génétiques
Néoplasmes
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs primitives multiples : Questions médicales les plus fréquentes",
"headline": "Tumeurs primitives multiples : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs primitives multiples : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-01",
"dateModified": "2026-02-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs primitives multiples"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs",
"url": "https://questionsmedicales.fr/mesh/D009369",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs",
"code": {
"@type": "MedicalCode",
"code": "D009369",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs primitives multiples",
"alternateName": "Neoplasms, Multiple Primary",
"code": {
"@type": "MedicalCode",
"code": "D009378",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jing Wang",
"url": "https://questionsmedicales.fr/author/Jing%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China."
}
},
{
"@type": "Person",
"name": "Ahmed Ali",
"url": "https://questionsmedicales.fr/author/Ahmed%20Ali",
"affiliation": {
"@type": "Organization",
"name": "Medical Oncology, Howard University Hospital, Washington, DC, USA."
}
},
{
"@type": "Person",
"name": "Peng Li",
"url": "https://questionsmedicales.fr/author/Peng%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China."
}
},
{
"@type": "Person",
"name": "H Kanani",
"url": "https://questionsmedicales.fr/author/H%20Kanani",
"affiliation": {
"@type": "Organization",
"name": "United Lincolnshire Hospitals NHS Trust, UK."
}
},
{
"@type": "Person",
"name": "N Gandhi",
"url": "https://questionsmedicales.fr/author/N%20Gandhi",
"affiliation": {
"@type": "Organization",
"name": "United Lincolnshire Hospitals NHS Trust, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Multiple neoplasms in patients with uveal melanoma: a systematic review.",
"datePublished": "2024-06-22",
"url": "https://questionsmedicales.fr/article/38909111",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10792-024-03164-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epidemiology, Pattern, and Survival of Multiple Primary Malignant Neoplasms in Southeast Iran: Results of Kerman Population-Based Cancer Registry 2014-2020.",
"datePublished": "2024-07-01",
"url": "https://questionsmedicales.fr/article/39068556",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2024.25.7.2257"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intracranial ependymoma in an adult patient with multiple primary malignancies.",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37643822",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-254584"
}
},
{
"@type": "ScholarlyArticle",
"name": "Germline whole genome sequencing in adults with multiple primary tumors.",
"datePublished": "2023-07-22",
"url": "https://questionsmedicales.fr/article/37481477",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10689-023-00343-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genomic characteristics and immune landscape of super multiple primary lung cancer.",
"datePublished": "2024-02-15",
"url": "https://questionsmedicales.fr/article/38364701",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ebiom.2024.105019"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs primitives multiples",
"item": "https://questionsmedicales.fr/mesh/D009378"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs primitives multiples - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs primitives multiples",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs primitives multiples",
"description": "Comment diagnostiquer des tumeurs primitives multiples ?\nQuels tests sont utilisés pour le diagnostic ?\nLes marqueurs tumoraux sont-ils utiles ?\nComment différencier les tumeurs primaires ?\nLes antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs primitives multiples",
"description": "Quels sont les symptômes courants ?\nLes symptômes sont-ils similaires pour toutes les tumeurs ?\nComment les symptômes évoluent-ils ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nLes symptômes dépendent-ils de l'emplacement des tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs primitives multiples",
"description": "Peut-on prévenir les tumeurs primitives multiples ?\nLes dépistages réguliers sont-ils recommandés ?\nQuels facteurs de risque peuvent être modifiés ?\nL'exposition à des substances chimiques est-elle un risque ?\nLe dépistage génétique est-il utile ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs primitives multiples",
"description": "Quels traitements sont disponibles ?\nLa chimiothérapie est-elle efficace pour toutes les tumeurs ?\nQu'est-ce que l'immunothérapie ?\nLa radiothérapie est-elle toujours nécessaire ?\nComment choisir le traitement approprié ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs primitives multiples",
"description": "Quelles complications peuvent survenir ?\nLes tumeurs multiples augmentent-elles les risques ?\nComment gérer les effets secondaires des traitements ?\nLes complications affectent-elles la qualité de vie ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs primitives multiples",
"description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il le risque ?\nLes infections peuvent-elles être un facteur de risque ?\nL'exposition professionnelle est-elle un risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D009378#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer des tumeurs primitives multiples ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des examens d'imagerie, biopsies et antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent IRM, TDM, échographie et analyses histopathologiques."
}
},
{
"@type": "Question",
"name": "Les marqueurs tumoraux sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains marqueurs peuvent aider à identifier des néoplasies spécifiques."
}
},
{
"@type": "Question",
"name": "Comment différencier les tumeurs primaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse histologique et les caractéristiques cliniques aident à les distinguer."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de tumeurs multiples."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais incluent douleur, fatigue, perte de poids et anomalies cutanées."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils similaires pour toutes les tumeurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, chaque type de tumeur peut présenter des symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps, nécessitant une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent imiter d'autres conditions, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Les symptômes dépendent-ils de l'emplacement des tumeurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'emplacement influence les symptômes, par exemple, les tumeurs pulmonaires causent la toux."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs primitives multiples ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives, comme un mode de vie sain, peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des tumeurs."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque peuvent être modifiés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac, l'alcool et adopter une alimentation équilibrée sont des facteurs modifiables."
}
},
{
"@type": "Question",
"name": "L'exposition à des substances chimiques est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines substances chimiques peuvent augmenter le risque de développer des tumeurs."
}
},
{
"@type": "Question",
"name": "Le dépistage génétique est-il utile ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut identifier des prédispositions héréditaires à des tumeurs multiples."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chirurgie, chimiothérapie, radiothérapie et immunothérapie."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace pour toutes les tumeurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, son efficacité dépend du type de tumeur et de son stade."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'immunothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunothérapie utilise le système immunitaire pour combattre les tumeurs."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle toujours nécessaire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle est utilisée selon le type de tumeur et la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Comment choisir le traitement approprié ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix dépend du type de tumeur, de son stade et de l'état général du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation des tumeurs, infections et effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Les tumeurs multiples augmentent-elles les risques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent augmenter le risque de complications et de récidives."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des soins de soutien, médicaments et suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une surveillance et un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux, l'exposition à des carcinogènes."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le HPV, sont liées à un risque accru de cancer."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle est-elle un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines professions exposent à des substances cancérigènes, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des tumeurs multiples."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 19/02/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
Medical Oncology, Howard University Hospital, Washington, DC, USA.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
United Lincolnshire Hospitals NHS Trust, UK.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
United Lincolnshire Hospitals NHS Trust, UK.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
United Lincolnshire Hospitals NHS Trust, UK.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
United Lincolnshire Hospitals NHS Trust, UK.
Publications dans "Tumeurs primitives multiples" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology/Hepatology, Charité University Medical Center Berlin, Campus Virchow Klinikum and Charité Mitte, Augustenburger Platz 1, 13353 Berlin, Germany.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Endocrinology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Endocrinology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Endocrinology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Orthopaedics, Pukou Central Hospital, PuKou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Publications dans "Tumeurs primitives multiples" :
1 publication dans cette catégorie
Affiliations :
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Publications dans "Tumeurs primitives multiples" :
Uveal melanoma is the most prevalent intraocular malignancy in adults, derived from uveal tract melanocytes. This study focuses on the frequency and risk of second primary malignancies in UM patients....
A PubMed search (1980-2023) identified studies on SPM incidence in UM patients. From 191 references, 14 studies were chosen, focusing on UM, SPMs, and analysing data on demographics and types of neopl...
Among 31,235 UM patients in 14 studies, 4695 had 4730 SPMs (15.03% prevalence). Prostate (15%), breast (12%), and colorectal (9%) cancers were most common. Digestive system malignancies were highest (...
The study highlights a significant presence of SPMs in UM patients, with an increasing trend in frequency over time, emphasizing prostate and breast cancers. This underscores the need for focused surv...
Cancer survivors may experience a subsequent primary cancer that affects their survival and quality of life. This study aimed to investigate the epidemiology of multiple primary malignant neoplasms (M...
In this retrospective cohort study, all patients who had been diagnosed with primary cancers and registered with the Kerman Cancer Registry Program (KPBCR) during 2014-2020 were included. MPMNs were d...
Of 26,315 patients registered with a primary cancer diagnosis, 492 (1.86%) developed subsequent primary cancers. The most common type of secondary cancer was skin and mucosa (n=131, 26.63%) followed b...
Both patients and physicians should be taught about the importance of prevention and the provision of care and screening services among cancer survivors. Studying the epidemiology, susceptibility, and...
The incidence of multiple primary malignancies (MPM) is increasing, and therefore, it has become highly important for clinicians to consider the concept of MPM when treating oncology patients. In this...
Multiple primary tumors (MPTs) are a harbinger of hereditary cancer syndromes. Affected individuals often fit genetic testing criteria for a number of hereditary cancer genes and undergo multigene pan...
In recent years, a growing number of patients with multiple primary lung cancer (MPLC) are being diagnosed, and a subset of these patients is found to have a large number of lesions at the time of dia...
Here, we perform whole exome sequencing (WES) and immunohistochemistry (IHC) analysis of PD-L1 and CD8 on 212 tumor samples from 42 patients with super MPLC....
We report the genomic alteration landscape of super MPLC. EGFR, RBM10 and TP53 mutation and TERT amplification are important molecular events in the evolution of super MPLC. We propose the conception ...
Our study depicts the genomic characteristics and immune landscape, providing insights into the pathogenesis and possible therapeutic guidance of super MPLC....
A full list of funding bodies that supported this study can be found in the Acknowledgements section....
Long-term survivors of cutaneous malignant melanoma (CMM) risk subsequent malignancies due to both host-related and environmental risk factors. This retrospective population-based study differentially...
The cohort study (1999-2018) included 9,726 CMM survivors (M = 4,873, F = 4,853) recorded by the cancer registry of all 5,000,000 residents in the Italian Veneto Region. By excluding subsequent CMM an...
Irrespective of the site, the SIR for synchronous cancers increased in both sexes (SIR = 1.90 in males and 1.73 in females). Both sexes also demonstrated an excess risk for synchronous kidney/urinary ...
Among CMM survivors, the risk of metachronous non-skin cancers is higher than in the general population and differs significantly by sex. These results encourage sex-tailored interventions for metachr...
The CDKN2A gene remains understudied in melanoma compared to BRAF alterations. Inactivation of this tumor suppressor gene through homozygous deletions in the 9p21 chromosomal region leads to cellular ...
Multiple primary cancers once thought to be rare have become increasingly common as the lifespan of cancer survivors has increased with availability of better and more effective cancer treatment. Howe...
The aim of this study is to study the epidemiologic characteristics of multiple primary cancers in the eastern region of India....
The study was conducted in the Department of Surgical Oncology, Medical College, Kolkata, from 2017 to 2020 over a period of 3 years. All patients with a diagnosis of second primary as per Internation...
Fifty cases of multiple primary tumors were identified, out of which 21 were synchronous while rest 29 were metachronous type. The male-female ratio was 1:1.2. The median age at presentation for index...
This is the first comprehensive study on multiple primary cancers and the largest so far in India. Our study overcomes the shortcoming of previous case series from our subcontinent. The merits of our ...
Multiple primary lung cancers (MPLCs) pose diagnostic and therapeutic challenges in clinic. Here, we orchestrated the cellular and spatial architecture of MPLCs by combining single-cell RNA-sequencing...
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma worldwide. The emergence of multiple primary malignancies (MPMs) has been described as a new progn...
To investigate the morbidity, incidence, and survival of MPM in DLBCL, we retrospectively reviewed the characteristics of 788 patients with DLBCL....
Forty-two patients were diagnosed with MPM, and 22 of them were diagnosed with subsequent primary malignancies (SPM) by pathologic biopsy. The incidence of SPM was associated with older age. Germinal ...
These data provide a comprehensive view of MPM in DLBCL. MPM was an independent prognostic factor of DLBCL in univariate analysis....